Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients

Relapse in patients after Bacillus Calmette-Guerin (BCG) treatment remains a concern. Here, Arjun Balar, MD, from NYU Langone Health Perlmutter Cancer Center, New York City, NY, discusses clinically meaningful results from the KEYNOTE-057 Phase II study of pembrolizumab therapy in HR non-muscle-invasive bladder cancer (NMIBC) patients unresponsive to BCG therapy (NCT02625961). Treatment of patients treated with pembrolizumab had encouraging antitumor activity as well as a low toxicity profile. Dr Balar explains that once the durability of responses to pembrolizumab is assessed, pembrolizumab therapy could become a promising treatment for BCG-unresponsive NMICB. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.